CastleKnight Management’s BioNTech BNTX Stock Holding History

CastleKnight Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6,500	Closed	-$976K	–	276
2022 Q4	$976K	Hold	6,500	–	–	0.13%	98
2022 Q3	$877K	Hold	6,500	–	–	0.12%	102
2022 Q2	$969K	Hold	6,500	–	–	0.16%	102
2022 Q1	$1.11M	Buy	6,500 +1,300	+25%	+$218K	0.16%	116
2021 Q4	$1.34M	Buy	+5,200	New	+$1.42M	0.28%	75

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

CastleKnight Management's BNTX Position: Q1 2023 in Review

CastleKnight Management sold out of BioNTech (BNTX) in Q1 2023, closing a stake of 6,500 shares — an estimated $976K sold.

CastleKnight Management first reported a position in BNTX in Q4 2021 and held it in 5 quarters. The position peaked at $1.34M in Q4 2021. 282 funds tracked by Wall St. Rank hold BNTX as of Q1 2023.

CastleKnight Management reported no remaining BioNTech position as of Q1 2023 after selling out during the quarter.
CastleKnight Management sold 6,500 BioNTech shares in Q1 2023, an estimated $976K.
CastleKnight Management first reported a position in BioNTech in Q4 2021 and held it in 5 quarters.
CastleKnight Management's BioNTech position peaked at $1.34M in Q4 2021.
282 funds tracked by Wall St. Rank held BioNTech as of Q1 2023.

Based on CastleKnight Management's 13F filing for Q1 2023, filed 15 May 2023.